[1]
|
曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(3): 145-149.
|
[2]
|
Iwai, Y., Hamanishi, J., Chamoto, K., et al. (2017) Cancer Immunotherapies Targeting the PD-1 Signaling Pathway. Journal of Biomedical Science, 24, 26. https://doi.org/10.1186/s12929-017-0329-9
|
[3]
|
Clarke, J.M., George, D.J., Lisi, S. and Salama, A.K.S. (2018) Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. Targeted Oncology, 13, 1-20. https://doi.org/10.1007/s11523-017-0549-7
|
[4]
|
Li, X., Shao, C., Shi, Y. and Han, W. (2018) Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy. Journal Hematology & Oncology, 11, 31. https://doi.org/10.1007/s11523-017-0549-7
|
[5]
|
Chen, J., Jiang, C.C., Jin, L. and Zhang, X.D. (2016) Regulation of PD-L1: A Novel Role of Pro-Survival Signalling in Cancer. Annals of Oncology, 27, 409-416. https://doi.org/10.1093/annonc/mdv615
|
[6]
|
Balar, A.V. and Weber, J.S. (2017) PD-1 and PD-L1 Antibodies in Cancer: Current Status and Future Directions. Cancer Immunology, Immunotherapy, 66, 551-564. https://doi.org/10.1007/s00262-017-1954-6
|
[7]
|
De Palma, M., Biziato, D. and Petrova, T.V. (2017) Microenvironmental Regulation of Tumour Angiogenesis. Nature Reviews Cancer, 17, 457-474. https://doi.org/10.1038/nrc.2017.51
|
[8]
|
Quail, D.F. and Joyce, J.A. (2013) Microenvironmental Regulation of Tumor Progression and Metastasis. Nature Medicine, 19, 1423-1437. https://doi.org/10.1038/nm.3394
|
[9]
|
Hanahan, D. and Coussens, L.M. (2012) Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell, 21, 309-322. https://doi.org/10.1016/j.ccr.2012.02.022
|
[10]
|
Nagy, J.A., Chang, S.H., Shih, S.C., Dvorak, A.M. and Dvorak, H.F. (2010) Heterogeneity of the Tumor Vasculature. Seminars in Thrombosis and Hemostasis, 36, 321-331. https://doi.org/10.1055/s-0030-1253454
|
[11]
|
Hobbs, S.K., Monsky, W.L., Yuan, F., et al. (1998) Regulation of Transport Pathways in Tumor Vessels: Role of Tumor Type and Microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 95, 4607-4612. https://doi.org/10.1073/pnas.95.8.4607
|
[12]
|
Jain, R.K. (1988) Determinants of Tumor Blood Flow: A Review. Cancer Research, 48, 2641-2658.
|
[13]
|
Noman, M.Z., Desantis, G., Janji, B., et al. (2014) PD-L1 Is a Novel Direct Target of HIF-1 α and Its Blockade under Hypoxia Enhanced MDSC-Mediated T Cell Activation. Journal of Experimental Medicine, 211, 781-790.
https://doi.org/10.1084/jem.20131916
|
[14]
|
Sitkovsky, M.V., Kjaergaard, J., Lukashev, D. and Ohta, A. (2008) Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia. Clinical Cancer Research, 14, 5947-5952.
https://doi.org/10.1158/1078-0432.CCR-08-0229
|
[15]
|
Zhou, Y., Miao, J., Wu, H., et al. (2017) PD-1 and PD-L1 Expression in 132 Recurrent Nasopharyngeal Carcinoma: The Correlation with Anemia and Outcomes. Oncotarget, 8, 51210-51223. https://doi.org/10.18632/oncotarget.17214
|
[16]
|
Huang, Y., Stylianopoulos, T., Duda, D.G., Fukumura, D. and Jain, R.K. (2013) Benefits of Vascular Normalization Are Dose and Time Dependent—Letter. Cancer Research, 73, 7144-7146.
https://doi.org/10.1158/0008-5472.CAN-13-1989
|
[17]
|
Voron, T., Colussi, O., Marcheteau, E., et al. (2015) VEGF-A Modulates Expression of Inhibitory Checkpoints on CD8+ T Cells in Tumors. Journal of Experimental Medicine, 212, 139-148. https://doi.org/10.1084/jem.20140559
|
[18]
|
Motz, G.T., Santoro, S.P., Wang, L.P., et al. (2014) Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors. Nature Medicine, 20, 607-615. https://doi.org/10.1038/nm.3541
|
[19]
|
Griffioen, A.W. (2008) Anti-Angiogenesis: Making the Tumor Vulnerable to the Immune System. Cancer Immunology, Immunotherapy, 57, 1553-1558. https://doi.org/10.1007/s00262-008-0524-3
|
[20]
|
Huang, Y., Goel, S., Duda, D.G., Fukumura, D. and Jain, R.K. (2013) Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. Cancer Research, 73, 2943-2948.
https://doi.org/10.1158/0008-5472.CAN-12-4354
|
[21]
|
Tian, L., Goldstein, A., Wang, H., et al. (2017) Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming. Nature, 544, 250-254. https://doi.org/10.1038/nature21724
|
[22]
|
Reck, M., Mok, T.S.K., Nishio, M., et al. (2019) Atezolizumab plus Bevacizumab and Chemotherapy in Non-Small-Cell Lung Cancer (IMpower150): Key Subgroup Analyses of Patients with EGFR Mutations or Baseline Liver Metastases in a Randomised, Open-Label Phase 3 Trial. The Lancet Respiratory Medicine, 7, 387-401.
https://doi.org/10.1016/S2213-2600(19)30084-0
|
[23]
|
Zhang, Z., Zhou, Y., Hu, K., Li, Z., Wang, Z. and Huang, Y. (2019) Complete Response of Early Stage Hepatocellular Carcinoma in a Patient Treated with Combination Therapy of Camrelizumab (SHR-1210) and Apatinib. Digestive and Liver Disease, 51, 1488-1490. https://doi.org/10.1016/j.dld.2019.07.005
|
[24]
|
Lee, M., Ryoo, B.Y., Hsu, C.H., et al. (2019) Randomised Efficacy and Safety Results for Atezolizumab (Atezo) + Bevacizumab ve (Bev) in Patients (PTS) with Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC). Annals of Oncology, 30, v875. https://doi.org/10.1093/annonc/mdz394.030
|
[25]
|
Zhang, W., Bi, X.Y., Sun, Y.K., et al. (2020) Preliminary Results of Sintilimabplus Different Dose of IBI305 (Anti-VEGF Monoclonal Antibody) Inpatients with Advanced Hepatocellular Carcinoma: A Phase Ib Study. Journal of Clinical Oncology, 38, 3079. https://doi.org/10.1200/JCO.2020.38.15_suppl.3079
|
[26]
|
Rini, B.I., Powles, T., Atkins, M.B., et al. (2019) Atezolizumab plus Bevacizumab ve versus Sunitinb in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial. The Lancet, 393, 2404-2415. https://doi.org/10.1016/S0140-6736(19)30723-8
|
[27]
|
Rini, B.I., Plimack, E.R., Stus, V., et al. (2019) Pembrolizumab plus Axitinib versus Sunitinb for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 380, 1116-1127. https://doi.org/10.1056/NEJMoa1816714
|
[28]
|
Motzer, R.J., Penkov, K., Haanen, J., et al. (2019) Avelumab plus Axitinib versus Sunitinb for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 380, 1103-1115. https://doi.org/10.1056/NEJMoa1816047
|
[29]
|
Fukuoka, S., Hara, H., Takahashi, N., et al. (2020) Regorafenib plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology, 38, 2053-2061. https://doi.org/10.1200/JCO.19.03296
|
[30]
|
Hochster, H.S., Bendell, J.C., Cleary, J.M., et al. (2017) Efficacy and Safety of Atezolizumab (Atezo) and Bevacizumab (bev) in a Phase Ib Study of Microsatellite Instability (MSI)-High Metastatic Colorectal Cancer (mCRC). Journal of Clinical Oncology, 35, 673-673. https://doi.org/10.1200/JCO.2017.35.4_suppl.673
|